Search research articles
Contact Us
Filters
Showing results (11-20 of 75) with videos related to
Page
of 8
Sort By:
Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons
|
October 14, 2008
Correlation between craniofacial and condylar path asymmetry
Takashi Hashimoto, Shingo Kuroda, Lihua E, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
June 27, 2024
Bispecific Antibody Use in Patients With Lymphoma and Multiple Myeloma
Adam Braun, Sushanth Gouni, Astrid Pulles, et al.
British Journal of Haematology
|
October 10, 2025
Real-world experience with CAR-T therapy in relapsed and refractory follicular lymphoma
Nicolás Triantafilo, Arnab Chowdhury, Swetha Thiruvengadam, et al.
Journal for Immunotherapy of Cancer
|
March 24, 2017
Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy
Ryan Urak, Miriam Walter, Laura Lim, et al.
Blood Advances
|
June 10, 2020
ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma
Steven I Park, Thomas C Shea, Oludamilola Olajide, et al.
Blood Research
|
October 13, 2018
Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma
Adam M Greenbaum, Damian J Green, Leona A Holmberg, et al.
Blood Advances
|
October 26, 2021
Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
Craig A Portell, Nolan A Wages, Brad S Kahl, et al.
Leukemia & Lymphoma
|
October 31, 2025
Copanlisib in combination with venetoclax in patients with relapsed/refractory mantle cell lymphoma
Paolo Lopedote, Geoffrey Shouse, Lu Chen, et al.
British Journal of Haematology
|
July 21, 2022
A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma
Paolo Strati, Morton Coleman, Rebecca Champion, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
March 12, 2010
Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation
Scott E James, Philip D Greenberg, Michael C Jensen, et al.
Page
of 8
Search research articles
Search
Showing results (11-20 of 75) with videos related to
Sort By:
Page
of 8
Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons
|
October 14, 2008
Correlation between craniofacial and condylar path asymmetry
Takashi Hashimoto, Shingo Kuroda, Lihua E, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
June 27, 2024
Bispecific Antibody Use in Patients With Lymphoma and Multiple Myeloma
Adam Braun, Sushanth Gouni, Astrid Pulles, et al.
British Journal of Haematology
|
October 10, 2025
Real-world experience with CAR-T therapy in relapsed and refractory follicular lymphoma
Nicolás Triantafilo, Arnab Chowdhury, Swetha Thiruvengadam, et al.
Journal for Immunotherapy of Cancer
|
March 24, 2017
Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy
Ryan Urak, Miriam Walter, Laura Lim, et al.
Blood Advances
|
June 10, 2020
ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma
Steven I Park, Thomas C Shea, Oludamilola Olajide, et al.
Blood Research
|
October 13, 2018
Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma
Adam M Greenbaum, Damian J Green, Leona A Holmberg, et al.
Blood Advances
|
October 26, 2021
Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
Craig A Portell, Nolan A Wages, Brad S Kahl, et al.
Leukemia & Lymphoma
|
October 31, 2025
Copanlisib in combination with venetoclax in patients with relapsed/refractory mantle cell lymphoma
Paolo Lopedote, Geoffrey Shouse, Lu Chen, et al.
British Journal of Haematology
|
July 21, 2022
A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma
Paolo Strati, Morton Coleman, Rebecca Champion, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
March 12, 2010
Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation
Scott E James, Philip D Greenberg, Michael C Jensen, et al.
Page
of 8